Evidence map›Paper›PMID 27994659›Full record

ArticleJournal of Cancer2016

Interferon-Tau has Antiproliferative effects, Represses the Expression of E6 and E7 Oncogenes, Induces Apoptosis in Cell Lines Transformed with HPV16 and Inhibits Tumor Growth

Herbey Oswaldo Padilla-Quirarte, Cesar Trejo-Moreno, Geny Fierros-Zarate, Jhoseline Carnalla Castañeda, Marie Palma-Irizarry, Eva Hernández-Márquez, Ana Isabel Burguete-Garcia, Oscar Peralta-Zaragoza, Vicente Madrid-Marina, Kirvis Torres-Poveda and 1 more

Open access · goldAbstract read
In one paragraph

Article in Journal of Cancer, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.6field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 1 institution in 1 country.

Herbey Oswaldo Padilla-QuirarteDivision of Chronic Infection and Cancer, National Institute of Public Health, Av. Universidad 655, Cuernavaca, Morelos. Mexico, 62100.
Cesar Trejo-MorenoDivision of Chronic Infection and Cancer, National Institute of Public Health, Av. Universidad 655, Cuernavaca, Morelos. Mexico, 62100.
Geny Fierros-ZarateDivision of Chronic Infection and Cancer, National Institute of Public Health, Av. Universidad 655, Cuernavaca, Morelos. Mexico, 62100.
Jhoseline Carnalla CastañedaDivision of Chronic Infection and Cancer, National Institute of Public Health, Av. Universidad 655, Cuernavaca, Morelos. Mexico, 62100.
Marie Palma-IrizarryDivision of Chronic Infection and Cancer, National Institute of Public Health, Av. Universidad 655, Cuernavaca, Morelos. Mexico, 62100.
Eva Hernández-MárquezDivision of Chronic Infection and Cancer, National Institute of Public Health, Av. Universidad 655, Cuernavaca, Morelos. Mexico, 62100.
Ana Isabel Burguete-GarciaDivision of Chronic Infection and Cancer, National Institute of Public Health, Av. Universidad 655, Cuernavaca, Morelos. Mexico, 62100.
Oscar Peralta-ZaragozaDivision of Chronic Infection and Cancer, National Institute of Public Health, Av. Universidad 655, Cuernavaca, Morelos. Mexico, 62100.
Vicente Madrid-MarinaDivision of Chronic Infection and Cancer, National Institute of Public Health, Av. Universidad 655, Cuernavaca, Morelos. Mexico, 62100.
Kirvis Torres-PovedaDivision of Chronic Infection and Cancer, National Institute of Public Health, Av. Universidad 655, Cuernavaca, Morelos. Mexico, 62100.
Victor Hugo Bermúdez-MoralesDivision of Chronic Infection and Cancer, National Institute of Public Health, Av. Universidad 655, Cuernavaca, Morelos. Mexico, 62100.
Instituto Nacional de Salud Pública · MX

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Interferon tau (IFN-τ) is a promising alternative antiviral and immunotherapeutic agent in a wide variety of diseases including infectious, neurodegenerative, autoimmune and cancer due to its low toxicity in comparison with other type I interferon´s. The objective of our study was established the effect of the bovine IFN-τ on human (SiHa) and murine (BMK-16/myc) cells transformed with HPV 16 and evaluates the antitumor effect in a murine tumor model HPV 16 positive. We determine that bovine IFN-τ has antiproliferative effects, pro-apoptotic activity and induces repression of viral E6 and E7 oncogenes (time- and dose-dependent) on human and murine cells transformed with HPV 16 similar to the effects of IFN-β. However, IFN-τ induces greater antiproliferative effect, apoptosis and repression of both oncogenes in BMK-16/myc cells compared to SiHa cells. The differences were explained by the presence and abundance of the type I interferon receptor

Indexed as

Human papillomavirusIFN-τimmunotherapy.oncogenes

Identifiers

PMID27994659
PMCPMC5166532
OpenAlexW2561793630

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.